Research Article

Meta-Analysis of the Therapeutic Effect of Shenqi Jiangtang Granule on Type 2 Diabetes Mellitus

Table 1

Principal characteristics of the studies included in the meta-analysis.

ReferenceSample size (C/T)Gender (male/female)Age (range, mean)Treatment methodTreatment cycle (week)Measurement index

Zhang et al., 2019 [21]60/60T: 31/29C: 33/27T: 45–67 (57.13 ± 9.86)C: 42–69 (57.46 ± 9.74)T: SQJT + Metformin + GlimepirideC: Metformin + Glimepiride121、2、3、4
Sui 2019 [22]52/52T: 30/22C: 31/21T: 39–68 (54.31 ± 5.11)C: 38–67 (53.25 ± 4.70)T: SQJT + Metformin + RosiglitazoneC: Metformin + Rosiglitazone121、2、4
Liu and Gao, 2017 [23]20/20T: 23/14C: 10/10T: 41–65 (56.55 ± 7.17)C: 42–65 (55.30 ± 7.36)T: SQJT + MetforminC: Metformin121、2、3、4
Sun, 2017 [24]48/48T: 28/20C: 30/18T: 38–64 (56.27 ± 4.61)C: 36–62 (54.15 ± 4.29)T: SQJT + MetforminC: Metformin81、2、3、4
Wang, 2016 [25]69/69T: 43/26C: 41/28T: 25–65 (54.3 ± 3.2)C: 26–65 (53.2 ± 3.4)T: SQJT + Metformin + Insulin glargineC: Metformin + Insulin glargine121、2、3、4
Yang, 2017 [26]40/40T: 21/19C: 22/18T: 42–65 (55.8 ± 8.9)C: 45–64 (55.4 ± 6.8)T: SQJT + MetforminC: Metformin242、3、4
Chen, 2018 [27]52/52T: 32/20C: 31/21T: 26–63 (55.2 ± 3.5)C: 27–60 (54.3 ± 3.7)T: SQJT + MetforminC: Metformin122、3、4
Fan and Gao, 2014 [28]40/40T: 22/18C: 24/16T: 42–74C: 40–73T: SQJT + MetforminC: Metformin121、2、3、4
Zhang, 2019 [29]49/49T: 29/20C: 31/18T: 40–75 (59.18 ± 7.66)C: 43–74 (60.27 ± 6.34)T: SQJT + MetforminC: Metformin123、4
Song, 2018 [30]36/36T: 21/15C: 20/16T: 43–76 (59.12 ± 10.83)C: 41–74 (58.94 ± 10.15)T: SQJT + LiraglutideC: Liraglutide121、2、3、4
Li, 2015 [31]42/42T: 27/15C: 26/16T: 53–68 (63.1 ± 6.6)C: 54–69 (62.8 ± 6.2)T: SQJT + RepaglinideC: Repaglinide41、2、3、4
Wang, 2013 [32]42/42T: 26/16C: 27/15T: 35–66 (45.9 ± 7.4)C: 33–63 (43.5 ± 5.2)T: SQJT + MetforminC: Metformin81、2、3、4
Liu, 2018 [33]30/30T: 14/16C: 13/17T: 60–76 (67.2 ± 9.4)C: 60–78 (66.8 ± 10.2)T: SQJT + MetforminC: Metformin122、3

Note. 1. Efficient; 2. FBG; 3. PBG; 4. HbA1c.